Biotechnology company Apogee Therapeutics has shared positive data for its potential best-in-class treatment for mild-to-moderate asthma. 

Zumilokibart (APG77) was assessed in a Phase Ib double-blind, placebo-controlled trial of 19 adult patients with mild-to-moderate asthma. Results show the treatment was well-tolerated and offered a robust and durable suppression of FeNO, a biomarker of Type 2 inflammation which correlates with exacerbations in asthma. 

“This first dataset of zumilokibart in a respiratory condition is very promising and showcases the potential of this treatment to help a new patient population,” said Mario Castro, M.P.H. Chief of Pulmonary, Critical Care, and Sleep Medicine at the University of Kansas.  

“With little innovation in the asthma space, the need for new treatment options that provide strong efficacy while decreasing treatment frequency is paramount. These data, in particular the deep and durable FeNO suppression, highlight the promise of this drug for patients with Type 2 asthma, and I look forward to continued evaluation of zumilokibart in upcoming studies.” 

“The results from this study further emphasise the versatility of zumilokibart across Type 2 inflammatory diseases, now spanning both dermatology and respiratory indications,” added Carl Dambkowski, Chief Medical Officer of Apogee.  

“With a favourable safety profile, as well as durable FeNO suppression, zumilokibart has the potential to serve as a foundational therapy – both as a monotherapy and in combination. Further, in patients in the APEX Phase 2 Part A trial with comorbid asthma or sinusitis, we saw improvement in asthma and sinusitis, as measured by improvements in ACQ-5 and SNOT-22, respectively, solidifying zumilokibart’s potential to broadly impact Type 2 inflammatory diseases.” 

Apogee intends to further evaluate zumilokibart in the ASPIRE asthma trial, as well as reporting clinical readouts for its atopic dermatitis treatments. 

Bruno Quinney, Content Team, DDW